Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

PHASE3CompletedINTERVENTIONAL
Enrollment

452

Participants

Timeline

Start Date

November 21, 2022

Primary Completion Date

August 15, 2025

Study Completion Date

August 15, 2025

Conditions
Agitation,PsychomotorBipolar I DisorderBipolar II DisorderSchizophreniaSchizoaffective DisorderSchizophreniform Disorders
Interventions
DRUG

BXCL501

Sublingual Film

DRUG

Matching Placebo

Sublingual Placebo Film

Trial Locations (24)

20877

BioXcel Clinical Research Site 103, Gaithersburg

33122

BioXcel Clinical Research Site 131, Miami

33186

BioXcel Clinical Research Site 124, Miami

44122

BioXcel Clinical Research Site 122, Beachwood

60123

BioXcel Clinical Research Site 130, Elgin

75062

BioXcel Clinical Research Site 125, Irving

75093

BioXcel Clinical Research Site 127, Plano

75115

BioXcel Clinical Research Site 102, DeSoto

78754

BioXcel Clinical Research Site 136, Austin

80209

BioXcel Clinical Research Site 129, Denver

89102

BioXcel Clinical Research Site 118, Las Vegas

89119

BioXcel Clinical Research Site 137, Las Vegas

90015

BioXcel Clinical Research Site 121, Los Angeles

90230

BioXcel Clinical Research Site 110, Culver City

90703

BioXcel Clinical Research Site 128, Cerritos

90706

BioXcel Clinical Research Site 113, Bellflower

91730

BioXcel Clinical Research Site 133, Rancho Cucamonga

91945

BioXcel Clinical Research Site 117, Lemon Grove

92056

BioXcel Clinical Research Site 123, Oceanside

92506

BioXcel Clinical Research Site 114, Riverside

92845

BioXcel Clinical Research Site 108, Garden Grove

92868

BioXcel Clinical Research Site 104, Orange

98201

BioXcel Clinical Research Site 126, Everett

08009

BioXcel Clinical Research Site 105, Berlin

Sponsors
All Listed Sponsors
collaborator

Worldwide Clinical Trials

OTHER

lead

BioXcel Therapeutics Inc

INDUSTRY